XGEVA Improves Metastasis-Free Survival In Castrate-Resistant Prostate Cancer
Cancer Care Cost To Jump by 27 Percent In a Decade, Reaching $158 Billion in 2020
Lilly Suspends Phase III Trial Of Tasisulam in Melanoma
Genomic Health Presents Meta-Analyses of Oncotype DX
In Phase II Study, NKTR-102 Shows Objective Response
Iniparib Plus Chemo Shows Benefit In Phase II Study
ColoPrint Improves Prognosis In Stage II and III Colon Cancer
Test May Identify Predictors For Recurrence Post-Surgery
Tissue of Origin Test Consistent With Diagnosis In Blinded Validation Study
Clinical Trials Approved By NCI CTEP Last Month
FDA Approves SNDA For Gardasil For Anal Cancer And Precancerous Lesions
Trending Stories
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Cancer patients with Medicare Advantage have access to fewer providers than Medicare patients, cross-sectional study finds
- A chronotherapy study in Nature Medicine showed dramatic results. Then it was retracted.
The phase III trial claimed a staggering boost to OS and PFS when immunochemotherapy was given before 3 p.m. - Did peer review fail? Nature Medicine’s chronotherapy paper retraction raises questions
- A new diagnostic lens—and a lasting scientific legacy
- OMB’s plan to increase political control of science faces stiff opposition on Capitol Hill
